High galectin-3 levels in patients with severe COVID-19 led Gaughan and coworkers to propose the pharmacological galectin-3 inhibitor GB0139 as a potential therapeutic approach in COVID-19-related pneumonitis. This evidence concerns the gene LGALS3 and COVID-19.